Brentuximab vedotin (INN trade name Adcetris) is an antibody-drug conjugate (ADC) directed to the protein CD30 which is expressed in classical Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).On 28 February 2011 Seattle Genetics submitted a Biologics License Application or BLA to the U.S.
This page contains content from the copyrighted Wikipedia article "Brentuximab vedotin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
